CALCA and migraine disorder: When measured by the 50% migraine responder rate, CGRP monoclonal antibody was related to a higher response rate than the placebo group (RR = 1.56, 95% CI: 1.37 to 1.76, p < 0.001), with low heterogeneity (I2 = 32%).